Biotech Values

[jq1234]

GILD ION-1, 2, 3 data from NEJM:

ION-1: Trt naive - For patients with cirrhosis, SVR12 ranged from 94 to 100% among patients with cirrhosis.

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1402454

ION-2: Trt experienced - For patients with cirrhosis who were as- signed to 12 weeks of treatment, the rates of sustained virologic response were 86% for those who received ledipasvir–sofosbuvir and 82% for those who received ledipasvir–sofosbuvir plus ribavirin.

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1316366

[I pooled ION-1, 2 together for cirrhotic patients, SVR12 is 91% for sofo/ledi, 93% for sofo/ledi plus RBV]

ION-3: Trt naive.

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1402355